Tratamiento farmacológico actual de la hipertensión arterial pulmonar / Pharmacological treatment of pulmonary arterial hypertension
Arch. cardiol. Méx
;
77(supl.4): S4-198-S4-201, oct.-dic. 2007. ilus
Article
in Spanish
| LILACS
| ID: lil-568692
ABSTRACT
Until recent years, pulmonary arterial hypertension was considered as an untreatable disease. However, with the better knowledge in its pathobiology, new drugs have been developed. These new drugs can be divided in three main groups 1. Prostacyclin analogs (Epoprostenol, iloprost, treprostinil); 2. Endothelin antagonists (Bosentan, sitaxsentan); and 3. Phosphodiesterase-5 inhibitors (Sildenafil). Numerous studies have evaluated the safety and efficacy of these drugs, showing significant improvement in exercise capacity, quality of life and time to worsening. Some of them have even showed a better survival when compared with conventional treatment. Despite these advances, pulmonary arterial hypertension remains an incurable disease, so the focus of new studies is the combination of two or more drugs with a different mechanism of action.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Hypertension, Pulmonary
Limits:
Humans
Language:
Spanish
Journal:
Arch. cardiol. Méx
Journal subject:
Cardiology
Year:
2007
Type:
Article
Affiliation country:
Mexico
Institution/Affiliation country:
Instituto Nacional de Cardiología Ignacio Chávez/MX
Similar
MEDLINE
...
LILACS
LIS